|
According to KG Zeroin MP Doctor (formerly Market Point) HLB closed up 13.68% at 53,600 won after securing about 206.9 billion won in strategic investment from U.K.based asset manager LMR Partners.
Affiliate stocks followed suit: HLB Life Science (+19.10%), HLB Pharmaceutical (+16.34%), HLB Therapeutics (+13.88%), HLB Panagene (+6.21%), and HLB Innovation (+5.57%) all gained, while HLB Biostep (278650) hit the upper limit (+29.98%), fueling investor optimism.
On Monday HLB announced plans to issue $140 million (about 199.8 billion won) in unseparated bonds with warrants (BW) to LMR Partners and $5 million (about 7.1 billion won) in exchangeable bonds (EB) through its affiliate HLB Life Science. Global investment bank UBS acted as sole underwriter.
HLB said 85% of the proceeds will be allocated to U.S. subsidiary Elevar Therapeutics for cancer drug development and global commercialization.
Market analysts said the deal marks a rare case of foreign capital entering a Korean biotech firm without a management control purpose, the first such large-scale investment since Temasek’s 2010 stake in Celltrion.
An HLB official said, “This marks the first inflow of overseas capital in the group’s history and recognition from global investors for our innovative drug development potential. We’ll accelerate Elevar’s global approval and commercialization to enhance corporate value.”
|
SK Bioscience rose 18.31% to close at 60,100 won after reporting strong third-quarter results, with consolidated revenue of 150.7 billion won and an operating loss of 19.4 billion won, narrowing the deficit by more than half year on year.
SK Bioscience attributed the improvement to steady contributions from its German subsidiary IDT Biologika, acquired in October 2024, and growing vaccine sales. The company’s cumulative 2025 revenue reached 467.2 billion won, more than quadruple the same period last year.
IDT has expanded its customer base in Europe and North America, bolstering its global CDMO (contract development and manufacturing organization) competitiveness through production efficiency and cost optimization.
Still, brokerage firms remain cautious. DB Financial Investment and Korea Investment & Securities both maintained a “Hold” rating in their latest reports, citing a need for more consistent earnings performance.
|
Diagnostic device maker Protea jumped 13.95% to 4,820 won after posting solid third quarter earnings.
The company reported revenue of 4.03 billion won, up 36.9% year over year operating profit of 1.18 billion won up 117.6%, and net income of 1.29 billion won surging 267.6% from a year earlier.
Protea recently launched the world’s first saliva based noninvasive immune diagnostic device IMSAFE Saliva which measures immunoglobulin A (IgA) levels within 15 minutes using just a few drops of saliva. The device eliminates the need for blood draws and can be stored at room temperature, improving distribution efficiency.
The company has already signed distribution contracts in Canada and other major markets and continues to expand its portfolio from allergy and antibiotic resistance testing to immune management. Protea aims to reach 50 billion won in annual sales within three years and 100 billion won within five.
A company spokesperson said “We will grow into a global diagnostic device leader built on our three core pillars immunity allergy and antibiotic resistance while ensuring both technological competitiveness and profitability.”







![[포토]'표정 어두운 김민석 대표'](https://image.edaily.co.kr/images/Photo/files/NP/S/2026/11/PS26111300806t.jpg)
![[포토]최민희-한민수-이성윤, '당 쇄신 촉구 기자회견...최고위는 불참'](https://image.edaily.co.kr/images/Photo/files/NP/S/2026/11/PS26111300793t.jpg)
![[포토]한국전력공사, AI코리아대상 사회적 책임상 수상](https://image.edaily.co.kr/images/Photo/files/NP/S/2026/11/PS26111201165t.jpg)
![[포토] 합격기원 소원지](https://image.edaily.co.kr/images/Photo/files/NP/S/2026/11/PS26111200934t.jpg)
![[SHOT+] 크리스찬 디올 CEO, 이대 명예박사 수여식](https://image.edaily.co.kr/images/Photo/files/NP/S/2026/11/PS26111200665t.jpg)
![[포토] 2026 이데일리 글로벌 AI포럼, '축사하는 하정우 부위원장'](https://image.edaily.co.kr/images/Photo/files/NP/S/2026/11/PS26111200659t.jpg)
![[포토] 델핀 아르노 크리스찬 CEO, 이대 명예박사](https://image.edaily.co.kr/images/Photo/files/NP/S/2026/11/PS26111200649t.jpg)
![[포토]행안위, '악수하는 윤호중-최용철'](https://image.edaily.co.kr/images/Photo/files/NP/S/2026/11/PS26111100820t.jpg)
![[포토]취재진 질문에 답하는 이용철 법무부 장관 후보자](https://image.edaily.co.kr/images/Photo/files/NP/S/2026/11/PS26111100701t.jpg)
![[포토]심사평하는 장효천 지방자치단체 행정대상 심사위원](https://image.edaily.co.kr/images/Photo/files/NP/S/2026/11/PS26111001347t.jpg)
![엔비디아 실적에 쏠린 눈…코스피 6000선 회복할까[주간증시전망]](https://image.edaily.co.kr/images/Photo/files/NP/S/2026/11/PS26111500289b.jpg)

